EVIDENCE LIBRARY
Do THC and CBD Produce the Same Central Effects?
A pharmacology review describes different THC and CBD effects in animal models, showing why findings about one cannabinoid cannot automatically be attributed to the other.
Short answer: No. A 2020 pharmacology review describes THC and CBD as distinct compounds with different receptor activity and different behavioral effects in animal models. Even when both compounds appeared beneficial in an experimental brain-injury model, the authors reported different proposed mechanisms.
What distinguishes THC from CBD?
THC is the principal psychoactive cannabinoid and acts partly through CB1 receptors in the brain. The review describes animal findings involving catalepsy-like immobility, spatial-memory impairment, and dose- and stimulus-dependent changes in ultrasonic vocalization.
CBD does not produce the same characteristic psychoactive profile and has very low affinity for CB1 and CB2 receptors. Its pharmacology may involve several other targets and pathways. That complexity makes it inaccurate to treat CBD as merely “THC without the high.”
What did the review describe about sensory behavior?
In the authors’ mouse work, THC altered low-frequency ultrasonic vocalizations after aversive air-puff stimulation. The direction of the response depended on THC dose and stimulus intensity. A CB1 antagonist and CBD, described in this setting as a negative allosteric modulator, reduced one THC-associated response, while a CB2 antagonist did not.
This is evidence of context-dependent receptor pharmacology in an animal assay. It is not a direct measure of human anxiety, perception, or impairment.
What about experimental brain injury?
The review also summarizes mouse middle-cerebral-artery-occlusion research in which THC and CBD improved brain-injury measures through different proposed pathways. A shared favorable endpoint therefore did not imply an identical molecular mechanism.
Why this matters in forensic interpretation
“Cannabis exposure” is not a complete toxicological description. Relevant variables include:
- the specific cannabinoid and its concentration;
- the THC-to-CBD ratio and other constituents;
- dose, route, and timing;
- the endpoint being measured; and
- whether evidence comes from cells, animals, controlled human studies, or case reports.
Animal behavior and stroke models can identify plausible mechanisms, but they cannot establish a person’s mental state, impairment, or treatment response. Conclusions should remain tied to the actual compound and evidence level.
Source
Mishima K, Irie K. Central Effect of Components of Cannabis: Utility and Risk. Yakugaku Zasshi. 2020;140(2):193–204. PubMed record (PMID 32009043).